Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17914
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHolmes, Natasha E-
dc.contributor.authorRobinson, J Owen-
dc.contributor.authorvan Hal, Sebastiaan J-
dc.contributor.authorMunckhof, Wendy J-
dc.contributor.authorAthan, Eugene-
dc.contributor.authorKorman, Tony M-
dc.contributor.authorCheng, Allen C-
dc.contributor.authorTurnidge, John D-
dc.contributor.authorJohnson, Paul D R-
dc.contributor.authorHowden, Benjamin P-
dc.date2018-03-05-
dc.date.accessioned2018-06-21T04:24:52Z-
dc.date.available2018-06-21T04:24:52Z-
dc.date.issued2018-03-05-
dc.identifier.citationBMC Infectious Diseases 2018; 18(1): 107en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17914-
dc.description.abstractVarious studies have identified numerous factors associated with poor clinical outcomes in patients with Staphylococcus aureus bacteraemia (SAB). A new study was created to provide deeper insight into in-hospital complications and risk factors for treatment failure. Adult patients hospitalised with Staphylococcus aureus bacteraemia (SAB) were recruited prospectively into a multi-centre cohort. The primary outcome was treatment failure at 30 days (composite of all-cause mortality, persistent bacteraemia, or recurrent bacteraemia), and secondary measures included in-hospital complications and mortality at 6- and 12-months. Data were available for 222 patients recruited from February 2011 to December 2012. Treatment failure at 30-days was recorded in 14.4% of patients (30-day mortality 9.5%). Multivariable analysis predictors of treatment failure included age > 70 years, Pitt bacteraemia score ≥ 2, CRP at onset of SAB > 250 mg/L, and persistent fevers after SAB onset; serum albumin at onset of SAB, receipt of appropriate empiric treatment, recent healthcare attendance, and performing echocardiography were protective. 6-month and 12-month mortality were 19.1% and 24.2% respectively. 45% experienced at least one in-hospital complication, including nephrotoxicity in 19.5%. This study demonstrates significant improvements in 30-day outcomes in SAB in Australia. However, we have identified important areas to improve outcomes from SAB, particularly reducing renal dysfunction and in-hospital treatment-related complications.en_US
dc.language.isoeng-
dc.subjectBacteraemiaen_US
dc.subjectComplicationen_US
dc.subjectMortalityen_US
dc.subjectStaphylococcus aureusen_US
dc.subjectTreatment failureen_US
dc.titleMorbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Infectious Diseasesen_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.affiliationDepartment of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology and Infectious Diseases, PathWest Laboratory Medicine-WA, Royal Perth Hospital, Perth, WA, Australiaen_US
dc.identifier.affiliationAustralian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, WA, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Camperdown, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of Western Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationInfection Management Services, Princess Alexandra Hospital, Woolloongabba, QLD, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of Queensland, St Lucia, QLD, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, University Hospital Geelong, Barwon Health, Geelong, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, Deakin University, Geelong, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Monash Health, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, Monash University, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Alfred Hospital, Prahran, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Epidemiology and Preventive Medicine, Monash University, Prahran, Victoria, Australiaen_US
dc.identifier.affiliationAustralian Commission on Safety and Quality in Health Care, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Paediatrics, University of Adelaide, Adelaide, SA, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology, Monash University, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationMicrobiological Diagnostic Unit, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australiaen_US
dc.identifier.doi10.1186/s12879-018-3011-2en_US
dc.type.contentTexten_US
dc.identifier.pubmedid29506483-
dc.type.austinJournal Article-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherHolmes, Natasha E
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.